• 1. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 2. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 3. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzene and substituted derivatives
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives

Recent Advances in the Study of 3-(Difluoromethyl)benzeneacetic Acid (CAS: 1000547-15-8)

3-(Difluoromethyl)benzeneacetic Acid (CAS: 1000547-15-8) has emerged as a compound of significant interest in the field of chemical biology and pharmaceutical research. This compound, characterized by its difluoromethyl group attached to a benzeneacetic acid backbone, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, pharmacological properties, and potential as a building block for more complex molecules in drug discovery.

One of the key areas of research has been the optimization of synthetic routes for 3-(Difluoromethyl)benzeneacetic Acid. A study published in the Journal of Medicinal Chemistry (2023) demonstrated a novel, high-yield synthesis method that reduces production costs and improves scalability. The method involves a palladium-catalyzed cross-coupling reaction, which has been shown to be highly efficient for introducing the difluoromethyl group into the benzeneacetic acid framework.

Pharmacological evaluations of 3-(Difluoromethyl)benzeneacetic Acid have revealed its potential as an anti-inflammatory agent. In vitro studies have shown that the compound inhibits key inflammatory mediators such as COX-2 and TNF-α, with an IC50 value comparable to existing non-steroidal anti-inflammatory drugs (NSAIDs). Further in vivo studies in rodent models have confirmed its efficacy in reducing inflammation with fewer gastrointestinal side effects than traditional NSAIDs.

Another promising application of 3-(Difluoromethyl)benzeneacetic Acid is in the development of kinase inhibitors. Researchers have utilized this compound as a core structure to design novel inhibitors targeting specific kinases involved in cancer progression. Preliminary results from cell-based assays indicate that derivatives of this compound show selective inhibition of certain oncogenic kinases while sparing normal cells, suggesting potential for targeted cancer therapies.

The metabolic stability and pharmacokinetic properties of 3-(Difluoromethyl)benzeneacetic Acid have also been investigated. Studies have shown that the difluoromethyl group enhances metabolic stability compared to non-fluorinated analogs, leading to improved oral bioavailability and longer half-life in preclinical models. These findings support its potential as a lead compound for further drug development.

Recent computational studies have provided insights into the molecular interactions of 3-(Difluoromethyl)benzeneacetic Acid with various biological targets. Molecular docking simulations have revealed that the difluoromethyl group plays a crucial role in forming stable hydrogen bonds with target proteins, explaining the observed biological activity. These computational models are being used to guide the design of more potent derivatives.

In conclusion, 3-(Difluoromethyl)benzeneacetic Acid (CAS: 1000547-15-8) represents a versatile compound with multiple therapeutic applications. Ongoing research continues to explore its potential in various disease areas, with particular focus on inflammation and oncology. The development of efficient synthetic methods and the elucidation of its mechanism of action provide a solid foundation for future drug discovery efforts centered around this promising chemical entity.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)